Pulmonary adenocarcinoma with microcystic histology and intratumoral heterogeneity of EGFR gene polymorphism

Histopathology

Volumn 57, Issue 1, 2010, Pages 112-120

  Yeh, Yi Chen ^a   Chou, Teh Ying ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

adenocarcinoma; EGFR; gene polymorphism; lung; microcystic

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; THYROID TRANSCRIPTION FACTOR 1; DNA; NUCLEAR PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; ASPIRATION BIOPSY; BONE METASTASIS; CANCER GROWTH; CANCER SIZE; CASE REPORT; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; FOLLOW UP; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LOBECTOMY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; THORAX WALL CANCER; ADENOCARCINOMA; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; ONCOGENE RAS; PATHOLOGY; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, ERBB-1; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS;

EID: 77954557778     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03595.x     Document Type: Article

References (27)

1. Bureau of Health Promotion. Cancer Registry Annual Report 2006.
2. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002 1 49 52.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat. Rev. Cancer 2007 7 778 790.
4. Colby TV, Noguchi M, Henschke C et al. Adenocarcinoma. In Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart.
5. Steinhauer JR, Moran CA, Suster S. 'Secretory endometrioid-like' adenocarcinoma of the lung. Histopathology 2005 47 219 220.
6. Tsao MS, Fraser RS. Primary pulmonary adenocarcinoma with enteric differentiation. Cancer 1991 68 1754 1757.
7. Arnould L, Drouot F, Fargeot P et al. Hepatoid adenocarcinoma of the lung: report of a case of an unusual alpha-fetoprotein-producing lung tumor. Am. J. Surg. Pathol. 1997 21 1113 1118.
8. Adachi H, Aki T, Yoshida H, Yumoto T, Wakahara H. Combined choriocarcinoma and adenocarcinoma of the lung. Acta Pathol. Jpn. 1989 39 147 152.
9. Marci V, Volante M, Cappia S et al. Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch. 2007 451 729 736.
10. Chou TY, Chiu CH, Li LH et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 2005 11 3750 3757.
11. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol. Int. 2007 57 233 244.
12. Mascaux C, Iannino N, Martin B et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 2005 92 131 139.
13. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004 350 2129 2139.
14. Tam IY, Chung LP, Suen WS et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res. 2006 12 1647 1653.
15. Benson DA, Karsch-Mizrachi I, Lipman DJ et al. GenBank. Nucleic Acids Res. 2006 34 D16 20.
16. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001 29 308 311.
17. Carlinfante G, Lazzaretti M, Ferrari S, Bianchi B, Crafa P. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol. Res. Pract. 2005 200 791 799.
18. Darling MR, Schneider JW, Phillips VM. Polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma: a review and comparison of immunohistochemical markers. Oral Oncol. 2002 38 641 645.
19. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod. Pathol. 2002 15 687 691.
20. Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP. Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 1999 86 207 219.
21. Lee VK, McCaughan BC, Scolyer RA. Polymorphous low-grade adenocarcinoma in the lung: a case report. Int. J. Surg. Pathol. 2004 12 287 292.
22. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 2007 13 2890 2896.
23. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008 99 929 935.
24. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J. Thorac. Oncol. 2008 3 527 529.
25. Nakano H, Soda H, Takasu M et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008 60 136 140.
26. Choi JE, Park SH, Kim KM et al. Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. BMC Cancer 2007 7 199.
27. Sasaki H, Endo K, Takada M et al. EGFR polymorphism of the kinase domain in Japanese lung cancer. J. Surg. Res. 2008 148 260 263.